SUDA ​- Faster, safer delivery for ex-blockbusters​

Stuart Roberts

Pitt Street Research and NDF Research

This week we've initiated coverage on SUDA, a Perth-based a drug delivery company focused on oral spray formulations of existing drugs. Imagine these five things:  

First, a small pharmaceutical company with a unique platform for reformulating billion-dollar drugs for oral delivery.  

Second, that such delivery is not only safer but also much faster-acting.  

Third, that the target markets are large, including patients suffering migraine, anxiety, erectile dysfunction, nausea and malaria.  

Fourth, that a reformulated approval potentially involves months (not years) and costs a few (not hundreds of) millions.  

Fifth, that the small pharma already has its first licensing deal with a top-20 global pharma, as well as two other recent deals.  Well, the small pharma is SUDA.  

We value it at 9 cents per share base case and 25 cents per share optimistic case using a probability-weighted DCF approach. Our target price of 17 cents per share sits at around the mid-point of valuation range.
 


1 stock mentioned

Stuart Roberts
Stuart Roberts
Founder and Senior Analyst
Pitt Street Research and NDF Research

I am an equity research professional who worked in stockbroking from 2001 to 2015. After 15 months doing investor relations I returned to equity research with the founding of NDF Research. With Marc Kennis I founded Pitt Street Research in July 2018.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment